|1.||Kim, Won-Ki: 2 articles (05/2004 - 01/2003)|
|2.||Kim, Hyoung-Chun: 2 articles (05/2004 - 01/2003)|
|3.||Shin, Eun-Joo: 2 articles (05/2004 - 01/2003)|
|4.||Jhoo, Wang-Kee: 2 articles (05/2004 - 01/2003)|
|5.||Mann, Henry J: 1 article (05/2011)|
|6.||Kumar, Atul: 1 article (05/2011)|
|7.||Remmel, Rory P: 1 article (05/2011)|
|8.||Beilman, Greg J: 1 article (05/2011)|
|9.||Liu, Ya-Juan: 1 article (01/2011)|
|10.||Wang, Jhi-Joung: 1 article (01/2011)|
|1.||Brain Ischemia (Cerebral Ischemia)
11/01/1991 - "We studied the dose response characteristics of dextrorphan's neuroprotective efficacy and side effects, correlating these beneficial and adverse responses with plasma and brain levels in a rabbit model of transient focal cerebral ischemia. "
09/17/1993 - "The dose-response curve and time window of efficacy for dextrorphan in permanent focal brain ischemia leading to infarction was studied in the rat. "
09/18/1989 - "We studied the efficacy of systemic pre-treatment with dextrorphan (DX), a clinically tested N-methyl-D-aspartate (NMDA) antagonist, in a rabbit model of transient focal cerebral ischemia. "
04/29/1996 - "Additive neuroprotective effects of dextrorphan and cycloheximide in rats subjected to transient focal cerebral ischemia."
02/01/1995 - "Dextrorphan hydrochloride is a noncompetitive N-methyl-D-aspartate antagonist that is neuroprotective in experimental models of focal brain ischemia. "
|2.||Wounds and Injuries (Trauma)
01/01/1993 - "Single-dose treatment with nalmefene, YM14673, or dextrorphan at 30 min after trauma each significantly improved behavioral recovery at two weeks as compared with vehicle-treated controls, confirming earlier studies with these agents. "
01/10/1990 - "Treatment with either dextrorphan or CPP, administered intrathecally 15 min after trauma, significantly improved chronic (4 weeks) behavioral recovery. "
03/02/1992 - "Pretreatment with dextrorphan attenuated the post-traumatic increase in extracellular levels of aspartate; although these differences did not reach significance when examined as absolute values, they were significant when analyzed as percent increase over pre-trauma baseline levels. "
05/19/1989 - "Treatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist dextrophan or the competitive antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid limited the resultant neurological dysfunction; dextrorphan treatment also improved the bioenergetic state after trauma and increased the intracellular free magnesium. "
01/10/1990 - "The potential role of N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of spinal cord injury was examined in rats by comparing the effects of the non-competitive NMDA antagonist dextrorphan and the competitive NMDA antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) on the behavioral and anatomical consequences of impact trauma to the spinal cord. "
09/17/1993 - "A dose-response study of dextrorphan in permanent focal ischemia."
04/01/1996 - "Dextrorphan (DX) 20-10 mg/kg given ip 15 min before ischemia reduced infarct volume in a dose-dependent manner with an apparent U-shaped dose-response curve; best protection was observed at 30 mg/kg. Posttreatment at 30 min, but not 60 min, was still effective. "
11/01/1991 - "These results demonstrate that systemic treatment with dextrorphan after 1 h focal ischemia can significantly protect against cerebral damage if adequate plasma and brain levels of dextrorphan are achieved. "
11/01/1991 - "One hour after the onset of ischemia, they were treated with an i.v. infusion of varying dextrorphan doses or normal saline. "
03/10/1988 - "DM and its active metabolite dextrorphan may prove to be clinically useful in protecting against hypoxia-ischemia."
01/01/1988 - "In the present study, the effects of dextrorphan were determined in an experimental model of seizure activity (maximal electroshock convulsions) (MES). "
01/01/2011 - "Dextrorphan did not produce any seizures. "
07/01/1996 - "Dextrorphan did not activate nor facilitate seizures."
01/01/1994 - "However, when dextrorphan was employed to suppress seizure-like events, later recurrent discharges did not develop during the remaining time course of the experiment. "
06/01/1993 - "Bay k-8644 (a Ca2+ channel agonist)-induced seizures were not antagonized by dextrorphan. "
02/01/1995 - "The purpose of this study was to determine the maximum loading dose and maintenance infusion of dextrorphan hydrochloride that are well tolerated in patients with an acute stroke. "
02/01/1995 - "An intravenous infusion of dextrorphan or placebo was begun within 48 hours of onset of a mild-to-moderate hemispheric stroke. "
09/15/1995 - "Dextrorphan HCl (Ro 01-6794/706) is an NMDA receptor antagonist with clinical potential for administration in an elderly population of acute ischemic stroke patients. "
02/01/1995 - "Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. "
09/15/1995 - "Severe hypotension, severe decreased levels of consciousness and respiratory depression should not be generally expected at loading doses less than 200 mg/hr. In summary, dextrorphan can be safely given to an elderly population of ischemic stroke patients as a loading dose rate below 200 mg/hr and as a maintenance dose rate between 50-90 mg/hr for 24 hours when patients are monitored carefully for pharmacologic effects."
|3.||3- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid (CPP)
|4.||Dizocilpine Maleate (Dizocilpine)
|5.||Protein Kinases (Protein Kinase)
|9.||Phencyclidine (Angel Dust)